Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 18/20 | 0.53 |
| ▸ | CA1 | P00915 | 12/20 | 0.53 |
| ▸ | CA12 | O43570 | 10/20 | 0.53 |
| ▸ | CA9 | Q16790 | 10/20 | 0.53 |
| ▸ | CA5A | P35218 | 6/20 | 0.53 |
| ▸ | CA7 | P43166 | 6/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.53 |
| ▸ | CA4 | P22748 | 4/20 | 0.53 |
| ▸ | CA6 | P23280 | 4/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397879 | 0.79 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL3639617 | 0.77 | CA2 (0.67) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL2674394 | 0.77 | CA2 (0.62) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL30870631 | 0.76 | CA2 (0.60) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL11516453 | 0.76 | CA2 (0.59) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL22664337 | 0.75 | CA2 (0.58) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL14289777 | 0.75 | CA2 (0.60) | SMN1; SMN2KDM4ECA2CA1CA12 | |
| SCHEMBL10174346 | 0.75 | HPGD (0.49) | SMN1; SMN2 | |
| SCHEMBL7632086 | 0.75 | CA2 (0.56) | KDM4ECA2 | |
| SCHEMBL20257139 | 0.73 | CA2 (0.61) | SMN1; SMN2KDM4ECA2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | SMN1; SMN2 932/4885KDM4E 2296/4885CA2 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.